89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC

Iris H. C. Miedema, Marc C. Huisman, Gerben J. C. Zwezerijnen, Rolf Grempler, Alejandro Perez Pitarch, Andrea Thiele, Raphael Hesse, Mabrouk Elgadi, Alexander Peltzer, Danielle J. Vugts, Guus A. M. S. van Dongen, Tanja D. de Gruijl, C. Willemien Menke-van der Houven van Oordt, Idris Bahce

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)

Abstract

Purpose: Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [89Zr]Zr-BI 754111 as a predictive imaging biomarker and investigated its target specific uptake as well as the correlation of its tumor uptake and the tumor immune infiltration. Methods: Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [18F]FDG-PET, patients were given 240 mg of BI 754091, followed 8 days later by administration of [89Zr]Zr-BI 754111 (37 MBq, 4 mg). PET scans were performed 2 h, 96 h, and 144 h post-injection. To investigate target specificity, a second tracer administration was given two weeks later, this time with pre-administration of 40 (N = 3) or 600 mg (N = 3) unlabeled BI 754111, followed by PET scans at 96 h and 144 h post-injection. Tumor immune cell infiltration was assessed by immunohistochemistry and RNA sequencing. Results: Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50–0.85]; 604 mg: 0.56 [IQR 0.42–0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. Conclusions: [89Zr]Zr-BI-754111 PET imaging shows favorable technical and biological characteristics for developing a potential predictive imaging biomarker for LAG-3-directed therapies. Trial registration: ClinicalTrials.gov, NCT03780725. Registered 19 December 2018.
Original languageEnglish
Pages (from-to)2068-2080
Number of pages13
JournalEuropean journal of nuclear medicine and molecular imaging
Volume50
Issue number7
Early online date2023
DOIs
Publication statusPublished - Jun 2023

Keywords

  • Immunotherapy
  • LAG-3
  • PD-1
  • PET
  • TILs
  • Zirconium-89

Cite this